Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural ValidationGlobeNewsWire · Oct 2, 2026
Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. ClearanceGlobeNewsWire · Sep 30, 2026
Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation PlatformGlobeNewsWire · Sep 24, 2026
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of DirectorsGlobeNewsWire · Sep 16, 2026
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026GlobeNewsWire · Sep 1, 2026
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy DeliveryGlobeNewsWire · Aug 26, 2026Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$6.40 | -$5.02 | Beat |
| Jun 4, 2026 | -$4.83 | -$4.83 | Beat |
| Feb 12, 2026 | -$7.56 | -$7.56 | Beat |
| Nov 14, 2025 | -$31.50 | -$28.98 | Beat |
| Aug 13, 2025 | -$18.59 | -$22.47 | Miss |
| May 29, 2025 | -$25.94 | -$38.54 | Miss |